Navigation Links
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
Date:7/8/2008

SAN MARINO, Calif., July 8 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy of Epeius Biotechnologies: that is, to demonstrate the profound single-agent efficacy of Rexin-G where traditional treatments have historically failed.

The FDA Orphan Drug Act was designed to encourage the development of new products that demonstrate significant promise for the treatment of very serious or life-threatening conditions that are relatively rare, affecting fewer than 200,000 persons in the United States. Orphan Drug Designation provides important economic incentives and powerful market protections that encourage the development of innovative products in the cancer field. U.S. Orphan Drug Designation provides seven years of market exclusivity for Rexin-G, a reduction in fees and taxes, and additional regulatory support for R&D initiatives.

About Rexin-G

Rexin-G, the lead product of Epeius Biotechnologies, is the first in a series of tumor-targeted anti-cancer agents designed to seek out and accumulate in metastatic cancers that have spread throughout the body, delivering a lethal payload of genetic medicine to tumor cells and their associated blood supplies without harming normal cells, tissues, or organ systems. Specifically designed to function within the context of the human circulatory system, the demonstration of single agent-efficacy by Rexin-G in Stage IV or metastatic osteosarcoma (ASCO, 2008) is an indication of the remarkable clinical potential of the precision targeting technologies embodied in its design. The
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
2. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Amyris Biotechnologies Announces $70 Million Series B Round
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... July 30, 2014 Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended June 30, 2014 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 1, 2011 Life Technologies Corporation (Nasdaq: ... webcasting management presentations to investors as part of the ... which is being held at the company,s headquarters in ...  Mark Stevenson, Life Technologies, President and Chief Operating Officer, ...
... NEW YORK, March 1, 2011 NeoStem, Inc. (NYSE Amex: ... in the U.S. and China, announced today that Dr. Robert ... Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been ... 6th Annual New York Stem Cell Summit. The Summit will ...
... BioNeutral Group, Inc. (OTC Bulletin Board: ... announced that its wholly-owned subsidiary, BioNeutral Services, Inc., has ... (KEDFA) to receive up to $280,000 in development incentives ... February 24 meeting, six companies, including BioNeutral Services, Inc., ...
Cached Biology Technology:Life Technologies to Webcast Investor Presentation as Part of the UBS West Coast Life Sciences & Diagnostics Bus Trip 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 2Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 3Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1 4BioNeutral Group to Receive Economic Development Incentives 2BioNeutral Group to Receive Economic Development Incentives 3
(Date:7/31/2014)... marine noise can affect animal movement and communication, with ... and Exeter and the cole Pratique des Hautes tudes ... stops embryonic development and increases larval mortality in sea ... Stylocheilus striatus used in this study) usually hatch ... on toxic alga but this study, conducted in a ...
(Date:7/30/2014)... at New York University is paving the way ... in civilians and military troops exposed to poisonous ... , An article in the current issue of ... in detoxifying organophosphates, which are compounds commonly used ... was developed by NYU School of Engineering Associate ...
(Date:7/30/2014)... in Lewis Carroll,s Through the Looking Glass, collaborators ... of Singapore improved a 35-year-old ecology model to ... millions of years. , The new model, called ... "Red Queen Effect," an evolutionary hypothesis introduced by ... that organisms must constantly increase their fitness (or ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... likely impact of ocean acidification on shellfish and other marine ... is published this week (date) in the journal Global ... because some of the increased carbon dioxide humans are adding ... water to produce an acid. The results suggest that ...
... by the National Science Foundation (NSF) found state agency ... fiscal year 2009, a 7 percent increase over the ... details nationwide and state-by-state totals of R&D activities performed ... first time survey data are available by individual state ...
... release is available in German . Tomato ... with a genetic defect that made the fruits mature very slowly, ... were delighted as it gave them more time to transport the ... it would be sold. At the stores, the tomatoes could then ...
Cached Biology News:New study helps predict impact of ocean acidification on shellfish 2New study helps predict impact of ocean acidification on shellfish 3Ethylene of no effect -- why peppers do not mature after picking 2
...
... suitable for sizing linear double-stranded DNA from 9 ... 13 bands consist of 8.3- to 48.5-kb fragments ... (cIind1ts857 Sam7). Ethidium bromide staining causes the four ... bp 12220 bp and 19399 bp) to show ...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
MarrowMAX Bone Marrow Medium...
Biology Products: